<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Persistent expression of certain oncogenes is required for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> maintenance </plain></SENT>
<SENT sid="1" pm="."><plain>This phenotype is referred to as oncogene <z:mp ids='MP_0002555'>addiction</z:mp> and has been clinically validated by anticancer therapies that specifically inhibit oncoproteins such as BCR-ABL, c-Kit, HER2, PDGFR, and EGFR </plain></SENT>
<SENT sid="2" pm="."><plain>Identifying additional genes that are required for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> maintenance may lead to new targets for anticancer drugs </plain></SENT>
<SENT sid="3" pm="."><plain>Although the role of aberrant Wnt pathway activation in the initiation of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> has been clearly established, it remains unclear whether sustained Wnt pathway activation is required for <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> maintenance </plain></SENT>
<SENT sid="4" pm="."><plain>To address this question, we used inducible β-catenin shRNAs to temporally control Wnt pathway activation in vivo </plain></SENT>
<SENT sid="5" pm="."><plain>Here, we show that active Wnt/β-catenin signaling is required for maintenance of <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> xenografts harboring APC mutations </plain></SENT>
<SENT sid="6" pm="."><plain>Reduced <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> upon β-catenin inhibition was due to cell cycle arrest and differentiation </plain></SENT>
<SENT sid="7" pm="."><plain>Upon reactivation of the Wnt/β-catenin pathway <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells resumed proliferation and reacquired a crypt progenitor phenotype </plain></SENT>
<SENT sid="8" pm="."><plain>In human <z:mp ids='MP_0009314'>colonic adenocarcinomas</z:mp>, high levels of nuclear β-catenin correlated with crypt progenitor but not differentiation markers, suggesting that the Wnt/β-catenin pathway may also control <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> cell fate during the maintenance phase of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in patients </plain></SENT>
<SENT sid="9" pm="."><plain>These results support efforts to treat human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> by pharmacological inhibition of the Wnt/β-catenin pathway </plain></SENT>
</text></document>